US-Based Biosimilar Supply Chain Redundancy for Commercial Distributors
Partner with us
Effective Q1 2027, our company, formerly known as Zeptide Pharma (and operating under the name Tirzepatide Pharma) will officially rebrand as MayMag Biologics. This strategic transition establishes a distinct corporate identity and eliminates market confusion between our company and the active pharmaceutical ingredient (API) generically known as Tirzepatide.
Large Scale 506e Biologics Manufacturer
What is an interchangeable biosimilar?
- It allows a similar medication to be substituted for its brand-name original right at the pharmacy counter without needing permission from the prescribing doctor
- MayMag-Generic Manufacturer of Sterile Injectable biosimilar biologics
- WFI, Epinephrine Pens, and Rheumatoid Auto Injectors
- Click here to download our FDA credentials
About Us
- We're not a retail 503b compounding pharma for hospitals and clinics.
- We are a 506 (e) specializing in large-scale manufacturing of generics drugs
- And biosimilar biologics for FDA-shortlisted drugs
Contact us to validate our FDA credentials
What sets us apart from other 506e pharmas
- We are local, based in the United States, with drug quality controlled and monitored.
- We have the scale, facility redundancy, and device supply chain to meet 100% of your market demand without a single day of backorder, with multiple FDA-compliant, GMP-certified facilities for both the active drug substance and the "fill-finish" final step.
- We understand how to handle the stability requirements of large batches, from formulation through transportation, without risking product degradation
- MayMag maintains device continuity assurance with in-house 510k auto device pen manufacturing, clean FDA Form 483 records, and zero warning letters
Bac-Water Manufacturer
The Science of Safety
- Bacteriostatic Water for Injection (BWFI) is crucial in modern medicine,
- Used to dilute or dissolve medications for injection.
- Contains 0.9% benzyl alcohol, which acts as a preservative.
- This allows vials to be safely re-entered multiple times for multi-dose applications.
Quality Control Assurance Framework at MayMag Biologics
What Sets Our 506e Facility Apart-We have the scale, facility redundancy, and device supply chain to meet 100% of your market demand without a single day of backorder
- The Science of Reliability of the Device Supply Chain
- Multiple FDA-compliant, GMP-certified facilities
- For both the active drug substance and the "fill-finish" final step
- Handles the stability requirements of large batches
- From formulation through transportation, without risking product degradation
- Clean FDA records and zero warning letters and USA based
Price Matters, But Supply Vulnerability Paralyzes the Market. Single-source biologic pipelines create chronic backorder risks for health systems.
- MayMag Biologics (formerly Zeptide Pharma)
- a 506e USA-based large-scale industrial manufacturer
- of insulin pens, anti-inflammatory auto pens, insulin nasal sprays, weight loss, and ophthalmology products
- Market-Ready Insulin 70/30 Biosimilar- Unmatched Supply Chain Resilience for US Distribution.
- Seamless operational continuity, robust device sourcing, and competitive commercial margin
Device-component bottlenecks (auto-pens) halt distribution even when API is plentiful. Regulatory and CMC failures at single sites disrupt downstream
- An IND outsourcing Facility for the development of once-a-week oral GLP1
- generic diabetic biosimilars, Bacteriostatic Water, lyophilized peptides,
- Specializes in generic drug manufacturing.
- De-Risked Insulin 70/30 Auto-Pen Distribution
- Multi-year, dual-sourced auto-pen manufacturing agreements
We manufacture 506e Products Only
Driving Volume Through Competitive, Predictable Unit Economics.
- Our manufacturing efficiency protects your distribution margins from pricing erosion. Our expertise spans a diversified portfolio of injectable and solid dose medications, supported by dependable international distribution
- Biologics and Insulin: Comprehensive manufacturing of insulin analogs (including aspart premix, aspart vials, glargine, and 70/30 pens), repurposed insulin, and advanced biosimilars.
- Targeted Therapeutics and GLP-1s: Cutting-edge development and production of oral GLP-1 therapeutics, advanced weight-loss treatments, and specialized peptides (Sterile and RUOs).
- Advanced Delivery Systems: Large-scale production of auto-pen medications, epinephrine auto-injectors (EpiPens), nasal sprays, transdermal drug delivery systems, and ophthalmology products.
- Custom Synthesis and API Manufacturing: Expert in-house HPLC drug purification and custom synthesis of DNA, RNA, oligonucleotides, wellness peptides, and human APIs.
- Pharmaceutical Manufacturing: Reliable production of Generic Medicines (OSDs), specialized Derma-Products, and bacteriostatic waters.
Our Biologics Portfolio
Insulin bulk supply contract and biosimilar insulin wholesale Manufacturer. MayMag Biologics is your source for
- Insulin 70/30 auto pen procurement
- premix insulin b2b supplier
- biosimilar auto pen manufacturers USA
- private label insulin manufacturer
- insulin rfp supplier
- wholesale generic insulin pens
MayMag Biologics is Your 506e Partner of Choice when looking for
- US-based insulin manufacturing facility
- insulin fill-finish contract manufacturing
- CMO for biologic drug-device combination
- biosimilar supply chain redundancy
- biologics cold chain manufacturer in USA
- insulin auto pen device sourcing
- high volume biosimilar CMO with USFDA, MHRA (UK), & Health Canada
- ANVISA (Brazil) & PMDA (Japan)
- PIC/S, GMP, TFDA, and the Gulf Cooperation Council (GCC)
MayMag inhalationTherapeutics
Innovative Biotechnology Solutions at MayMag Biologics Manufacturer
Join Our Team
Anti-inflammatory Autopen Manufacturing
Partner with us
For Customizable auto-injector drug delivery, "Prefilled insulin syringe contract manufacturing, USA insulin Biosimilar manufacturer, Affordable Insulin, us biosimilar manufacturer, insulin auto pen contract manufacturing, biosimilar insulin pen suppliers usa,